|
|
 Previous Article | Table of Contents | Next Article 
CD79a: a novel marker for B-cell neoplasms in routinely processed tissue
samples
DY Mason, JL Cordell, MH Brown, J Borst, M Jones, K Pulford, E Jaffe, E Ralfkiaer, F Dallenbach and H Stein
University Department of Cellular Science, John Radcliffe Hospital, Oxford,
UK.
The CD79 molecule, comprising two polypeptide chains, mb-1 (CD79a) and B29
(CD79b), is physically associated in the B-cell membrane with
immunoglobulin. It transmits a signal after antigen binding and may,
therefore, be considered the B cell equivalent of CD3. It appears before
the pre-B-cell stage, and the mb-1 (CD79a) chain can still be present at
the plasma cell stage. In this report, we describe a new anti-CD79a
monoclonal antibody, JCB117, which reacts with human B cells in paraffin
embedded tissue sections, including decalcified bone marrow trephines. When
tested on a total of 454 paraffin embedded tissue biopsies, gathered from a
number of different institutions, it reacted with the great majority (97%)
of B-cell neoplasms, covering the full range of B-cell maturation,
including 10 of 20 cases of myeloma/plasmacytoma. It is of interest that
the antibody labels precursor B-cell acute lymphoblastic leukemia samples,
making it the most reliable B-cell marker detectable in paraffin-embedded
specimens in this disorder. All neoplasms of T cell or nonlymphoid origin
were negative, indicating that antibody JCB117 may be of value to
diagnostic histopathologists for the identification of B-cell neoplasms of
all maturation stages.
Volume 86,
Issue 4,
pp. 1453-1459,
08/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N-T Ngo, C Brodie, C Giles, D Horncastle, M Klammer, I A Lampert, A Rahemtulla, and K N Naresh
The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome
J. Clin. Pathol.,
November 1, 2009;
62(11):
1009 - 1015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Deshmukh, K Elderfield, A Rahemtulla, and K N Naresh
Immunophenotype of neoplastic plasma cells in AL amyloidosis
J. Clin. Pathol.,
August 1, 2009;
62(8):
724 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y K O Teng, E W N Levarht, R. E M Toes, T. W J Huizinga, and J. M van Laar
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation
Ann Rheum Dis,
June 1, 2009;
68(6):
1011 - 1016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakagawa, M. Yamada, and Y. Suzuki
18F-FDG Uptake in Reactive Neck Lymph Nodes of Oral Cancer: Relationship to Lymphoid Follicles
J. Nucl. Med.,
July 1, 2008;
49(7):
1053 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al.
Novel markers of normal and neoplastic human plasmacytoid dendritic cells
Blood,
April 1, 2008;
111(7):
3778 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Flora, F. Brito-Babapulle, and K. N. Naresh
Aberrant positivity for CD79a in erythroid lineage cells a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment
Haematologica,
June 1, 2007;
92(6):
855 - 856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tiacci, S. Pileri, A. Orleth, R. Pacini, A. Tabarrini, F. Frenguelli, A. Liso, D. Diverio, F. Lo-Coco, and B. Falini
PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than CD79a and Selective Association with t(8;21)-Acute Myelogenous Leukemia
Cancer Res.,
October 15, 2004;
64(20):
7399 - 7404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Reynaud, N. Lefort, E. Manie, L. Coulombel, and Y. Levy
In vitro identification of human pro-B cells that give rise to macrophages, natural killer cells, and T cells
Blood,
June 1, 2003;
101(11):
4313 - 4321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Pileri, G. Gaidano, P. L. Zinzani, B. Falini, P. Gaulard, E. Zucca, F. Pieri, E. Berra, E. Sabattini, S. Ascani, et al.
Primary Mediastinal B-Cell Lymphoma: High Frequency of BCL-6 Mutations and Consistent Expression of the Transcription Factors OCT-2, BOB.1, and PU.1 in the Absence of Immunoglobulins
Am. J. Pathol.,
January 1, 2003;
162(1):
243 - 253.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Z. Rassenti and T. J. Kipps
Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion
Blood,
April 15, 2000;
95(8):
2725 - 2727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Thompson, J. A. Talley, H. N. Do, H. L. Kagan, L. Kunkel, J. Berenson, M. D. Cooper, A. Saxon, and R. Wall
Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia
Blood,
August 15, 1997;
90(4):
1387 - 1394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S. Brouns, E. d. Vries, J. J. Neefjes, and J. Borst
Assembled Pre-B Cell Receptor Complexes Are Retained in the Endoplasmic Reticulum by a Mechanism That Is Not Selective for the Pseudo-light Chain
J. Biol. Chem.,
August 9, 1996;
271(32):
19272 - 19278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
